Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 6/20 | 0.39 |
| ▸ | F13A1 | P00488 | 4/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706545 | 0.85 | POLB (0.42) | MEN1KMT2A | |
| SCHEMBL1417900 | 0.77 | ESR2 (0.45) | HTR6ESR2MEN1KMT2AMAPT | |
| SCHEMBL1417607 | 0.77 | ESR2 (0.45) | HTR6ESR2MEN1KMT2AMAPT | |
| SCHEMBL31079909 | 0.76 | MAPT (0.48) | ESR2MAPTGPR119NR1H2 | |
| SCHEMBL1992279 | 0.76 | MAPT (0.48) | ESR2MAPTGPR119NR1H2 | |
| SCHEMBL25680898 | 0.75 | HTR6 (0.54) | HTR6 | |
| SCHEMBL25259649 | 0.74 | HTR6 (0.41) | HTR6ESR2MEN1KMT2AMAPT | |
| SCHEMBL25680870 | 0.74 | HTR6 (0.38) | HTR6ESR2MEN1KMT2AGPR119 | |
| SCHEMBL22650893 | 0.73 | MAPT (0.46) | ESR2MAPTGPR119NR1H2 | |
| SCHEMBL24358981 | 0.73 | HTR6 (0.54) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | HTR6 1383/4885ESR2 1548/4885MEN1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.